SHARE
COPY LINK
EBOLA

EBOLA

‘Ebola watchlist man’ sent back to Austria

A 35-year-old Israeli businessman has told The Local he is extremely angry after Cypriot authorities prevented him from leaving a plane in Larnaca and sent him back to Vienna because he had travelled to Liberia in early December - which is one of the centres of the Ebola outbreak.

'Ebola watchlist man' sent back to Austria
A hospital isolation room. Photo: APA/HELMUT FOHRINGER

The businessman, who had been formally cleared for travel by US state authorities after being placed on a special monitoring programme, left Austria on Sunday for Cyprus.

On his arrival in Larnaca he was told he could not disembark, as the authorities mistakenly believed he had visited the West African country in the last 21 days.

He told The Local that he was not offered quarantine, but was made to leave on the same plane, which carried him along with a full flight of passengers back to Vienna.

A spokesperson for the man told The Local that he left Liberia on December 12th, and was therefore safely beyond the 21 day period for which the WHO has advised that visitors to such countries should be monitored.  

Subsequently, the man travelled to the US on December 20th, to be with his fiancée. While in the US, authorities there advised him he would only need to be monitored for a fever for an additional two weeks, given the known maximum incubation period for the disease is three weeks.

He was cleared for travel by US state authorities on January 2nd, and proceeded to travel via Austria to Cyprus, where the authorities there over-reacted, in his opinion.

The Cypriot health minister Philippos Patsalis assured all passengers on the flight in question that the man was examined upon his arrival in Larnaca, and was found not to have a fever, meaning he was at a very low risk for harbouring the virus.

In an exclusive interview, the man told The Local: "Since I left West Africa on December 12th, I have been open, honest, and compliant with all government health and immigration authorities concerned with the Ebola outbreak. It is good that governments, including my own, are aware of and tracking this public health crisis."

"However, it is very upsetting that, despite being out of West Africa for over 21 days, and despite having complied with US health authorities until the 21-day monitoring period ended on January 2nd, I was still detained on the plane in Cyprus and considered a health threat. A basic understanding of the virus makes it clear to anyone that there is no way I pose a threat, and I will be investigating further to determine how and why I was classified as such."

The man passed through Austria only en route to Cyprus, and is now returning to Israel to continue his business trip.

According to one of the other passengers on the plane, no one informed them regarding the possible threat, which they only discovered when told by Cypriot media.

“We were not even informed while at the airport, waiting for our luggage. The plane parked far away and someone came and brought us some forms to fill our data. We were even told that it is a procedural matter. After half an hour, we were released to go get our luggage. Again, no one informed us,” a passenger told the Cypriot news network Sigmalive.

Since 2014, there have been several suspected Ebola cases in Cyprus, although none of those examined resulted positive for the disease.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

EBOLA

Spanish researchers develop five-strain vaccine against lethal Ebola virus

Spanish researchers are working on a vaccine against all five strains of the killer Ebola virus in what would be a world first, Madrid's October 12 Hospital said Wednesday (July 11).

Spanish researchers develop five-strain vaccine against lethal Ebola virus
Ebola protects itself with proteins that act as a shield, and only exposes its vulnerable zones for short periods of time. Photo: AFP

A prototype vaccine developed by pharmaceutical group Merck is already in use, but acts only against the most virulent, “Zaire” strain.

Despite not having market approval, Merck's rVSV-ZEBOV was administered to people in the Democratic Republic of Congo in May, with UN approval, in a bid to contain an outbreak of the same virus that killed more than 11,300 in three West African countries from 2013 to 2015, sparking international panic.

For several months, a team from the October 12 Hospital has been working with researchers at two other hospitals in the capital to examine and learn from blood samples taken from three people cured of Ebola in Spain.

Lead researcher Rafael Delgado told reporters the difficulty lay in the fact that the virus protects itself with proteins that act as a shield, and only exposes its vulnerable zones for short periods of time.

That makes it tough for the body's immune system to fight the virus.

The three Spanish patients had produced “very effective” viral antibodies, though in a “small quantity” and only against the Zaire strain they were contaminated with.

Delgado, head of microbiology at the hospital, said researchers are aiming to reproduce these antibodies on a larger scale, and in a way that would make them efficient against all five virus strains.

US medical giant Johnson & Johnson is separately developing an experimental vaccine against two Ebola strains.

Delgado said researchers hope to get results from mouse experiments within a year.

The Ebola epidemic caused alarm in Spain in 2014 when a nursing assistant, Teresa Romero, became the first person infected outside Africa.

She caught the disease while tending to a Spanish missionary repatriated from Sierra Leone, who died in Spain in September that year.